

Supplementary Figure A. Impact of OST exposure at baseline or during follow-up in relation to HIV incidence among PWID. The sample in the pooled analysis includes 840 seroconversions over 24,519 person years of follow up. Note that unpublished data of Deren et al relates to the impact of MMT exposure at baseline in relation to HIV incidence at 36 months in Puerto Rican heroin injectors at two different sites (NYC: New York City, USA; PR: Bayamon, Puerto Rico).





Supplementary Figure B. Impact of OST in relation to HIV incidence among people who inject drugs by provision of monetary incentives associated with participation in the study (A) and duration over which OST exposure was assessed (B)



Supplementary Figure C. Funnel plot of nine studies included in meta-analysis of studies regarding the impact of OST in relation to HIV incidence among people who inject drugs. The symbol * denotes unpublished studies. Note that the central line is plotted at the fixed-effect summary effect (RR 0.56, 95% CI 0.47-0.68).